Following the recent publication of our paper on the use of Breath Biopsy® for the improved detection of liver disease, Med-Tech Innovation News have published an article, prepared by our Content Team, that explains the novel concept of exogenous volatile organic compound probes (EVOC® Probes). We demonstrated how the research linking limonene with liver disease validates the entire EVOC Probe approach, and discussed next steps in our efforts to identify a robust panel of biomarkers for liver diseases with the ultimate aim of developing a widely-available test for early stage disease detection and progression monitoring.
Find out more about what we're doing to develop tests for clinical use on our Breath Biopsy Tests page.
Typical biomarker discovery can feel like panning for gold, sifting through hundreds of possible factors captured from a specific method in the hope of finding ‘the one’ with clinical potential. But there is another way. [... EVOC Probes] are safe compounds that can be administered to assess targeted metabolic or disease processes [... and since they] aren’t found within the body itself, they provide a high contrast signal for detection